← Back

QCRI Frontiers of Cancer Research Presentation by Dr. Serisha Moodley

  • Event Start: Apr 05, 2018 4:00 pm
    Location: QCRI 100/01 Conf Rms.

    a QCRI Frontiers of Cancer Research Presentation!

    Serisha Moodley, PhD

    Post-doctoral Research Fellow, Mulligan Lab
    Division of Cancer Biology & Genetics,
    Queen’s Cancer Research Institute

    Thursday 05 April 2018 at 4:00 pm
    QCRI Conference Rooms 100/101

    Customizing Cancer Therapy: Molecular targeting of protein tyrosine kinases for the treatment of Lung Cancer

    Lung cancer is the leading cause of cancer-related death in Canada and worldwide. Altered expression including, activating mutations, translocations and amplifications, of protein tyrosine kinases (PTKs) have been identified in different types of lung cancers and are associated with poor patient survival. Advances in molecular technologies have led to the design and development of selective PTK-targeting drugs that have resulted in significant clinical improvements. Originally known as tyrphostins, small-molecule tyrosine kinase inhibitors (TKIs) were first developed in the early 1980s and based on the structure of natural low molecular weight compounds that inhibited PTKs like Src and EGFR. We will examine the current clinical treatment strategies and use of TKIs for the treatment of lung cancer. Currently approved TKIs act on multiple PTKs and are associated with adverse side effects. We will take a look at the next generation of TKIs that have demonstrated increased selectivity for a specific PTK and efficacy in lung cancer models.

    Everyone is welcome!